Sodium hydride → 4-[2-[[(1,3-benzodioxol-5-yl)methoxy]ethyl]piperidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine

HRID 434237

Reaktionsgleichung

Reaktionsgleichung von HRID 434237
[N:1]1([C:6]2[N:11]=[C:10]([N:12]3[CH2:17][CH2:16][CH2:15][CH2:14][CH:13]3[CH2:18][CH2:19][OH:20])[CH:9]=[CH:8][N:7]=2)[CH:5]=[CH:4][N:3]=[CH:2]1.[H-].[Na+].[CH2:23](Cl)[C:24]1[CH:32]=[CH:31][C:30]2[O:29][CH2:28][O:27][C:26]=2[CH:25]=1.[Cl-].C([NH3+])(C)(C)C>CN(C=O)C>[O:29]1[C:30]2[CH:31]=[CH:32][C:24]([CH2:23][O:20][CH2:19][CH2:18][CH:13]3[CH2:14][CH2:15][CH2:16][CH2:17][N:12]3[C:10]3[CH:9]=[CH:8][N:7]=[C:6]([N:1]4[CH:5]=[CH:4][N:3]=[CH:2]4)[N:11]=3)=[CH:25][C:26]=2[O:27][CH2:28]1

Komponenten

6

Edukt 4

HCID 24758Sodium hydrideHCID 887131,3-Benzodioxole, 5-(chloromethyl)-HCID 11355454t-Butylammonium chlorideHCID 224879671-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol

Produkt 1

HCID 229583294-[2-[[(1,3-benzodioxol-5-yl)methoxy]ethyl]piperidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidineAusbeute 35 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6228DimethylformamideLösungsmittel

Reaktionsbedingungen

Temperatur
80 °C

Versuchsvorschrift

The above synthesis may be carried out as follows: To DMF (100 ml) was added 4-chloro-2-imidazol-1-ylpyrimidine (0.50 g, 2.77 mmol), 2-piperidineethanol (0.359 g, 2.77 mmol), and Hünig's base (0.536 g, 4.15 mmol). After heating at 80° C for 5 hours, the solvent was removed in vacuo and the residue was chromatographed (CH2Cl2/MeOH, 19/1) to give 349 mg (46%) of 1-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol (the compound of formula (XVI)), (1H NMR (CDCl3) δ 8.54 (s, 2), 8.11 (d, 1), 7.82 (t, 1), 7.11 (d, 1), 6.44 (d, 1), 3.60 (m, 2), 3.03 (m, 1), 1.77 (m); MS: 274 (M+H)+). To a solution of 1-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol (25 mg, 0.092 mmol) dissolved in DMF (5 ml) was added NaH (60% dispersion in oil, 5.5 mg, 0.14 mmol) followed by piperonyl chloride (17 mg, 0.10 mmol) and t-butyl ammonium chloride. After stirring for 16 hours at 80° C., the solvent was removed in vacuo and the residue was partitioned with saturated NH4Cl and CH2Cl2. The organic layer was separated, dried (MgSO4), the solvent removed in vacuo, and the residue chromatographed (CH2Cl2/MeOH, 19/1) to give 13 mg (35%) of 4-[2-[[(1,3-benzodioxol-5-yl)methoxy]ethyl]piperidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine (the compound of formula (Icc)); 1H NMR (CDCl3) δ 8.52 (s, 1), 8.05 (d, 1), 7.80 (s, 1), 7.09 (s, 1), 6.73 (m, 3), 6.45 (d, 1), 5.93 (s, 2), 4.30 (s, 2), 3.45 (m, 2), 2.95 (m, 1), 1.55 (m); MS: 408.7 (M+H)+.

Aufarbeitung

  1. customthe solvent was removed in vacuo
  2. customthe residue was partitioned with saturated NH4Cl and CH2Cl2
  3. customThe organic layer was separated
  4. dry with materialdried (MgSO4)
  5. customthe solvent removed in vacuo
  6. customthe residue chromatographed (CH2Cl2/MeOH, 19/1)

Quellen und Nachweise

ORD-Eintrag
ord-89f043889a2548508fc06e5dcc7976dd
Quelldatensatz
uspto-grants-2003_12
Patentnummer
US06670473B2

Verknüpfte Notizen

Wird geladen…